Skip to main content

Table 3 Relationship of day 4 (end of infusion) values to 28-day mortality in PROWESS placebo patients

From: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

   Sample size Univariate odds ratio
Measure Cut-offa Higher risk Lower risk Odds ratio (95% CI) P
Protein C (%) <42 240 578 4.63 (3.35 to 6.41) <0.0001
Protein S (%) <42 297 521 3.25 (2.38 to 4.43) <0.0001
Antithrombin III (%) <60 306 512 4.17 (3.05 to 5.71) <0.0001
Interleukin-6 (pg/ml) ≥185.6 264 563 7.27 (5.23 to 10.11) <0.0001
Prothrombin time (seconds) ≥18.4 233 585 6.13 (4.40 to 8.56) <0.0001
D-dimer (μg/ml) ≥4.63 408 410 2.13 (1.57 to 2.89) <0.0001
Cardiovascular SOFA ≥3 301 539 7.32 (5.28 to 10.13) <0.0001
Respiratory SOFA ≥3 358 482 3.36 (2.48 to 4.56) <0.0001
Renal SOFA ≥1 335 505 4.82 (3.52 to 6.59) <0.0001
Hematologic SOFA ≥2 252 588 3.42 (2.50 to 4.68) <0.0001
Hepatic SOFA ≥1 256 573 2.11 (1.55 to 2.89) <0.0001
  1. aCut-off was defined by the day 4 (end of infusion) value that resulted in maximum sensitivity and specificity for predicting 28-day mortality. CI, confidence interal; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; SOFA, Sequential Organ Failure Assessment.